The vial kind of Remdesivir (Desrem) is still imported. We are producing Oseltamivir 75 mg in capsule form in the nation.
Jakarta – PT Indofarma is pursuing the production target of COVID-19 healing drugs– Remdesivir, Oseltamivir, and Ivermectin– to be attained throughout the July-September 2021 period in Indonesia.
” The vial kind of Remdesivir (Desrem) is still imported. We are producing Oseltamivir 75 mg in pill form in the country,” PT Indofarma President Director, Arief Pramuhanto, specified throughout a hearing (RDP) with the House of Representatives’ Commission VI held virtually here on Wednesday.
Remdesivir is still obtained through imports from India, and as numerous as 140 thousand vials are set up to arrive here on Sunday (July 11), he verified.
The additional 90 thousand vials will also arrive on Thursday (July 15), he kept in mind.
” Jointly, we will receive 230 thousand vials by this month. One vial is for one shot,” he specified.
For the Oseltamivir type, Indofarma will produce approximately 5 million pills per month up until August and September 2021, Pramuhanto kept in mind.
” We have prepared to produce 8 million pills or about 80 thousand boxes of Oseltamivir,” he specified.
Such medications have been set up to be produced due to the existing rise in need, he informed.
PT Indofarma is likewise increasing its production capacity of the Ivermectin kind of therapeutic drug for COVID-19 patients, doubling from the production in July 2021 of as many as eight million pills.
” During this month, as much as 8 million pills or around 400 thousand vials of Ivermectin will be produced, and next month, we will include some facilities to help double its production,” he said.
Associated news: COVID rise: SOE Minister guarantees of schedule of antiviral drugs
Associated news: Govt protects COVID-19 medication schedule till year end
MODIFIED BY INE
